AIDS Vaccine 200

Types of AIDS Vaccines

AV200Logo-new-2009

Check Presentation Chris-Bess Tina-Chang and Emory Vaccine Center Staff

AIDS Vaccine 200 is a term used to describe the various efforts and initiatives aimed at developing a vaccine to prevent Acquired Immunodeficiency Syndrome (AIDS), which is caused by the Human Immunodeficiency Virus (HIV). The development of an effective AIDS vaccine has been a major goal of the scientific and medical communities since the identification of HIV as the causative agent of AIDS in the early 1980s.

Background

AIDS is a life-threatening condition that severely weakens the immune system, making individuals susceptible to opportunistic infections and certain cancers. The HIV virus attacks and destroys CD4+ T cells, which are crucial for immune function. Despite significant advances in antiretroviral therapy (ART), which can manage HIV infection and prolong life, there is currently no cure for AIDS. An effective vaccine is considered essential for the long-term control and eventual eradication of the disease.

There are several types of AIDS vaccines under investigation, including:

• Preventive Vaccines: Designed to prevent HIV infection in individuals who are not yet infected.
• Therapeutic Vaccines: Aimed at improving the immune response in individuals who are already infected with HIV.
• Combination Vaccines: These may include both preventive and therapeutic components.

Challenges in Development

The development of an AIDS vaccine faces numerous challenges, including:

• Genetic Diversity of HIV: HIV exists in multiple subtypes and mutates rapidly, making it difficult to create a vaccine that is effective against all variants.
• Immune Evasion: HIV has evolved mechanisms to evade the immune system, complicating vaccine design.
• Lack of Natural Immunity: Unlike some other viruses, there are no known cases of individuals who have naturally cleared HIV infection, making it harder to identify immune responses that a vaccine should elicit.

Current Research

Research on AIDS vaccines is ongoing, with several candidates in various stages of clinical trials. Some of the notable approaches include:

• Viral Vector Vaccines: These use a harmless virus to deliver HIV genes into the body, prompting an immune response.
• Protein Subunit Vaccines: These use pieces of the HIV virus (such as proteins) to stimulate an immune response.
• DNA Vaccines: These involve injecting DNA that codes for HIV proteins, which are then produced by the body's cells and trigger an immune response.

Related Pages

• HIV
• AIDS
• Antiretroviral therapy
• CD4+ T cells
• Opportunistic infections
• Viral vector vaccine
• Protein subunit vaccine
• DNA vaccine